A Multicenter Cohort Study on Transarterial Chemoembolization with or Without Sorafenib for Intermediate-Stage Hepatocellular Carcinoma: Reconsidering Combination-Therapy Trial Design.
Yan Zhao,Hailiang Li,Wei Bai,Jueshi Liu,Weifu Lv,Sheng Guan,Xiao Qin,Wenhui Wang,Weixin Ren,Wei Mu,Weidong Guo,Shanzhi Gu,Yilong Ma,Zhanxin Yin,Wengang Guo,Yongji Wang,Jielai Xia,Rafael Duran,Daiming Fan,Guohong Han
DOI: https://doi.org/10.1200/jco.2015.33.15_suppl.4080
IF: 45.3
2015-01-01
Journal of Clinical Oncology
Abstract:4080 Background: The proof of the superiority of combination therapy with sorafenib and transarterial chemoembolization (TACE) over TACE alone for hepatocellular carcinoma (HCC) in term of survival is lacking. We conducted this multicenter retrospective study to evaluate the efficacy of combination therapy over TACE alone, and to compare the overall survival (OS) between patients with ≥ grade 2 sorafenib-related dermatologic adverse events (AEs) in the combination therapy group and patients treated with TACE alone. Methods: From January 2009 to December 2012, 606 consecutive patients with intermediate stage HCC, Eastern Cooperative Oncology Group performance status 0-1, and Child-Pugh class A-B ( ≤ 7) were included. Of them 202 received combination therapy and 404 received TACE alone therapy, respectively. Results: There was no significant difference between the two groups in median OS although a trend toward longer survival was observed in the combination therapy group (22.3 vs. 18.1 months, P= 0.281). After propensity score matching the difference in OS was still not different (22.3 vs. 17.9 months, P= 0.343). Of note, in the combination therapy group, 119 patients with ≤ grade 1 dermatologic AEs within the first two months of sorafenib initiation, which were defined as non-responders, had increased risk of death compared with 83 patients with ≥ grade 2 dermatologic AEs which were defined as responders (HR = 1.85; 95%CI 1.27-2.68; P= 0.001). By using the second propensity score matching to balance the baseline differences between responders subgroup and TACE alone group, a significantly prolonged median OS was observed in the responders subgroup (27.9 vs.18.3 months, P= 0.046). Conclusions: Combination therapy, not in all, but in responders to sorafenib, results in longer overall survival than TACE alone. Sorafenib-related dermatologic AEs may be considered a possible clinical marker to stratify responders from all patients. Before the appearance of any assured biomarkers, the design of prospective comparative studies needs to focus on the responders to treatment who are evaluated by clinical markers.